Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC
“These preliminary results suggest that HLD-0915, an oral, once daily therapy, can achieve meaningful anti-tumor activity with a clean safety profile in mCRPC patients who had failed up to 8 prior mCRPC therapies,” said Dr. Andrew Hahn, Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, who presented the HLD-0915 data in the oral plenary session. “Furthermore, HLD-0915 demonstrated clinical activity regardless of genomic heterogeneity – including androgen receptor (AR) mutations, splice variants or amplifications. Given the limited treatment options for mCRPC patients, these clinical findings support the differentiated approach to drive a precision cell-killing effect through a novel mechanism that does not rely on cancer drivers that can cause drug resistance.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data